1. Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer 
Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan Aebi, MD, Oliver Gautschi, MD 
Journal of Thoracic Oncology 
Volume 10, Issue 4, Pages e16-e17 (April 2015)
DOI: /JTO
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2. FIGURE 1
Histology with adenocarcinoma (hematoxylin and eosin staining) (A); immunohistochemistry with TTF1 expression (B); Sanger read with human epidermal growth factor receptor 2 (HER2) p.A775_G776insYVMA (C); and simultaneous HER2 immunohistochemistry and dual chromogenic in situ hybridization with HER2 overexpression (score 2+, brown color) and HER2 amplification (2.3 ratio of black HER2 and red CEP17 signals) (D).
Journal of Thoracic Oncology  , e16-e17DOI: ( /JTO )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3. FIGURE 2
18Fluorodeoxyglucose positron emission tomography and computer tomography scans 1 week before the start of trastuzumab emtansine (A, B, C); at the end of cycle 1 (D, E, F); and at the end of cycle 2 (G, H, I), showing rapid metabolic and morphologic response.
Journal of Thoracic Oncology  , e16-e17DOI: ( /JTO )
Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions